NCT01230138View on ClinicalTrials.gov

Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

May 31, 2012

Conditions
Plaque Psoriasis
Interventions
DRUG

Placebo

Placebo tablets

DRUG

FP187

High daily dose of 750mg administered as 250mg TID

DRUG

FP187

High daily dose of 750mg administered as 375mg BID

DRUG

FP187

Low daily dose of 500mg FP187 administered as 250mg BID

DRUG

FP187

Oral tablets, up to 3 times daily for 20 weeks.

Trial Locations (2)

20354

SCIderm, Hamburg

01307

Dermatological Dept., Uniklinikum, TU-Dresden, Dresden

Sponsors
All Listed Sponsors
lead

Forward-Pharma GmbH

INDUSTRY